胰腺癌治疗的新选择。
Emerging Therapeutic Options in Pancreatic Cancer Management.
机构信息
Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso', CNR, 80131 Naples, Italy.
出版信息
Int J Mol Sci. 2024 Feb 5;25(3):1929. doi: 10.3390/ijms25031929.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival rate of <8% [...].
摘要
胰腺导管腺癌 (PDAC) 是一种毁灭性疾病，5 年生存率<8%[...]。
相似文献
1
Emerging Therapeutic Options in Pancreatic Cancer Management.胰腺癌治疗的新选择。
Int J Mol Sci. 2024 Feb 5;25(3):1929. doi: 10.3390/ijms25031929.
2
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.致癌性 ERBB2 异常和 KRAS 突变协同促进胰腺导管腺癌的进展。
Carcinogenesis. 2020 Mar 13;41(1):44-55. doi: 10.1093/carcin/bgz086.
3
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.胰腺导管腺癌的药物治疗管理：当前与新兴概念
Drugs Aging. 2017 May;34(5):331-357. doi: 10.1007/s40266-017-0453-y.
4
Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.铁死亡在 PDAC 中的新兴潜在机制和治疗靶点：充满希望的未来。
Int J Mol Sci. 2022 Nov 30;23(23):15031. doi: 10.3390/ijms232315031.
5
Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.比较慢性胰腺炎和胰腺导管腺癌中基质细胞和导管上皮细胞的特征。
PLoS One. 2014 May 5;9(5):e94357. doi: 10.1371/journal.pone.0094357. eCollection 2014.
6
Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.靶向肿瘤微环境用于胰腺癌治疗
Chin Clin Oncol. 2019 Apr;8(2):18. doi: 10.21037/cco.2019.03.02.
7
Pancreatic ductal adenocarcinoma: metastatic disease.胰腺导管腺癌：转移性疾病。
Clin Transl Oncol. 2017 Dec;19(12):1423-1429. doi: 10.1007/s12094-017-1690-6. Epub 2017 Jun 16.
8
Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.胰腺导管腺癌患者淋巴细胞区室的监测与功能特征分析
Pancreatology. 2016 Nov-Dec;16(6):1069-1079. doi: 10.1016/j.pan.2016.07.008. Epub 2016 Jul 11.
9
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.免疫检查点抑制在胰腺导管腺癌中的应用：当前的局限性和未来的选择。
Front Immunol. 2018 Aug 15;9:1878. doi: 10.3389/fimmu.2018.01878. eCollection 2018.
10
Immunophenotypes of Ductal Epithelial Cells in Advanced Pancreatic Ductal Adenocarcinoma.高级胰腺导管腺癌中导管上皮细胞的免疫表型。
Digestion. 2019;99(3):247-251. doi: 10.1159/000492861. Epub 2018 Sep 11.
引用本文的文献
1
STK39-mediated amplification of γ-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance.STK39介导的γ-H2A.X扩增促进同源重组并导致对PARP抑制剂耐药。
Nucleic Acids Res. 2024 Dec 11;52(22):13881-13895. doi: 10.1093/nar/gkae1099.
本文引用的文献
1
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.抑制胰腺癌中的 RAF/MEK/ERK 信号级联：最新进展与未来展望。
Int J Mol Sci. 2024 Jan 28;25(3):1631. doi: 10.3390/ijms25031631.
2
Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study.与良性疾病相比，与胰腺导管腺癌相关的胆汁微生物组特征：一项英国初步研究。
Int J Mol Sci. 2023 Nov 28;24(23):16888. doi: 10.3390/ijms242316888.
3
IK Channel-Independent Effects of Clotrimazole and Senicapoc on Cancer Cells Viability and Migration.克霉唑和银杏酸对癌细胞活力和迁移的 IK 通道非依赖性影响。
Int J Mol Sci. 2023 Nov 14;24(22):16285. doi: 10.3390/ijms242216285.
4
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌免疫治疗的进展
Cancers (Basel). 2023 Aug 25;15(17):4265. doi: 10.3390/cancers15174265.
5
Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway.靶向 AHR 可通过 ELAVL1-DCK 通路增加胰腺癌细胞对吉西他滨的敏感性。
Int J Mol Sci. 2023 Aug 24;24(17):13155. doi: 10.3390/ijms241713155.
6
Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer.局部治疗与胰腺癌肿瘤微环境重塑
Int J Mol Sci. 2023 Aug 11;24(16):12681. doi: 10.3390/ijms241612681.
7
Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights.肠道微生物组在胰腺癌发生和治疗中的作用：新的认识。
World J Gastroenterol. 2023 Jul 7;29(25):3984-3998. doi: 10.3748/wjg.v29.i25.3984.
8
The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.癌症相关成纤维细胞（CAFs）与免疫细胞在影响胰腺癌免疫治疗疗效中的探戈。
Int J Mol Sci. 2023 May 13;24(10):8707. doi: 10.3390/ijms24108707.
9
Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study.外泌体 miRNA 生物标志物panel 用于患者血浆中胰腺导管腺癌的检测：一项初步研究。
Int J Mol Sci. 2023 Mar 7;24(6):5081. doi: 10.3390/ijms24065081.
10
An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma.外泌体 miRNA 标志物用于胰腺导管腺癌的检测。
Biosensors (Basel). 2022 Oct 6;12(10):831. doi: 10.3390/bios12100831.
Zotero 插件